{"id":70,"date":"2014-08-20T13:17:06","date_gmt":"2014-08-20T13:17:06","guid":{"rendered":"http:\/\/delveinsightblog.wordpress.com\/?p=70"},"modified":"2023-02-06T15:37:54","modified_gmt":"2023-02-06T10:07:54","slug":"ebola-virus-drugs-approved-or-still-in-pipeline-whats-the-mystery","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/ebola-virus-drugs-approved-or-still-in-pipeline-whats-the-mystery","title":{"rendered":"Ebola Virus Drugs Approved or Still in Pipeline. What\u2019s the mystery?"},"content":{"rendered":"\n
\n

Get informed about the Current Drugs in Pipeline with DelveInsight<\/span> <\/strong>\u201c’Ebola Viral<\/strong> Infections<\/strong>–Pipeline Insights<\/strong>, 2014<\/strong>\u2032, Report<\/span><\/em><\/p>\n<\/blockquote>\n\n\n\n

About Virus<\/strong><\/span>
<\/span><\/h3>\n\n\n\n

Ebola virus disease (formerly known as Ebola haemorrhagic fever) is a severe, often fatal illness, with a case fatality rate of up to 90%. Ebola first appeared in 1976 in 2 simultaneous outbreaks, in Nzara, Sudan, and in Yambuku, Democratic Republic of Congo. The latter was in a village situated near the Ebola River, from which the disease takes its name.<\/p>\n\n\n\n

The 2014 Ebola outbreak is one of the largest Ebola outbreaks in history and the first in West Africa. It is affecting four countries in West Africa: Guinea, Liberia, Nigeria, and Sierra Leone.<\/p>\n\n\n\n

Disease update<\/span><\/h3>\n\n\n\n

Confirmed, probable, and suspect cases and deaths from Ebola virus disease in Guinea, Liberia, Nigeria, and Sierra Leone, as of 16 August 2014<\/strong><\/h4>\n\n\n\n

Total Cases in West Africa<\/strong><\/span><\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Cases and Death by Country<\/strong><\/span><\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Vaccine and treatment<\/strong><\/span><\/p>\n\n\n\n

No licensed vaccine for EVD is available<\/strong>. Several vaccines are being tested, but none are available for clinical use.<\/p>\n\n\n\n

Fast Track Drugs in Pipeline<\/strong><\/span><\/p>\n\n\n\n

Tekmira<\/strong><\/span><\/p>\n\n\n\n

In March 5, 2014, U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of TKM-Ebola, an anti-Ebola viral therapeutic of Tekmira Pharmaceuticals Corporation.<\/strong><\/p>\n\n\n\n

The TKM-Ebola drug is being developed by Tekmira<\/strong> and the U.S. Department of Defense’s medical countermeasure systems biodefense therapeutics joint product management office under a $140 million contract.<\/p>\n\n\n\n

The anti-Ebola virus RNAi therapeutic has been used in preclinical studies to treat previously infected “non-human primates”, with results showing 100 percent protection from an otherwise lethal dose of Zaire Ebola virus.<\/p>\n\n\n\n

In January 2014, Tekmira commenced a Phase I clinical trial<\/strong> using TKM-Ebola. The TKM-Ebola Phase I clinical trial is a randomized, single-blind, placebo-controlled study involving single ascending doses and multiple ascending doses of TKM-Ebola. The study will assess the safety, tolerability and pharmacokinetics of administering TKM-Ebola to healthy adult subjects.<\/p>\n\n\n\n

RISK<\/strong><\/span><\/p>\n\n\n\n

KM-Ebola may not prove to be an effective anti-viral therapy for hemorrhagic fever viruses; data from the TKM-Ebola Phase I human clinical trial may not be available as currently anticipated, or at all; the U.S. Department of Defense may suspend or terminate its participation in the TKM-Ebola program; the Fast Track designation from the FDA may not result in faster development times or earlier approvals; and Tekmira’s products may not prove to be effective or as potent as currently believed.<\/p>\n\n\n\n

AVI-7537<\/strong><\/span><\/p>\n\n\n\n

On Sep 18, 2012, U.S. Food and Drug Administration (FDA) has granted Fast Track status for the development of Sarepta Therapeutic\u2019s lead infectious disease drug candidate, AVI-7537<\/strong>, a different type modified RNA molecule. AVI-7537<\/strong> is directed against one of the three Ebolavirus genes (VP24). The chemistry platform utilized for development is PMOplus. AVI-7537 also works via a different mechanism to block the viral protein from being made.<\/p>\n\n\n\n

Sarepta had been conducting Phase 1<\/strong> safety trials with the drug alone and together another Ebola-directed PMOplus molecule (AVI-7539, with the combination called AVI-6002).<\/p>\n\n\n\n

Currently Given Non-Licensed Drug<\/strong><\/span><\/p>\n\n\n\n

ZMapp<\/strong><\/span><\/p>\n\n\n\n

American missionary Ebola patients, Dr. Kent Brantly and Nancy Writebol are given biotech product, called ZMapp<\/strong>, are indeed still experimental \u2013 it\u2019s not yet approved for human use, and not yet even in phase I clinical trials.<\/p>\n\n\n\n

The ZMapp three-antibody cocktail isn\u2019t a vaccine. Instead, it provides an artifical immune response against sugar-tagged proteins on the outside of the Ebolavirus.<\/p>\n\n\n\n

ZMappTM is composed of three \u201chumanized\u201d monoclonal antibodies manufactured in, specifically Nicotiana. It is an optimized cocktail combining the best components of MB-003 (Mapp) and ZMAb (Defyrus\/PHAC). ZMappTM was first identified as a drug candidate in January 2014 and has not yet been evaluated for safety in humans.<\/p>\n\n\n\n

WHAT’S IN THE PIPELINE?<\/strong><\/span><\/p>\n\n\n\n

There are about a half dozen Ebola drugs and vaccines in development, several of which have received funding from the U.S. <\/strong><\/p>\n\n\n\n

For more information on Pipeline drugs of Ebola Virus get the DelveInsight\u2019s Report<\/em><\/strong> ‘Ebola Viral<\/em> Infections-Pipeline Insights<\/em>, 2014\u2032 in just $1250.<\/strong><\/span><\/p>\n\n\n\n

For more information contact info@delveinsight.com<\/a><\/span><\/p>\n\n\n\n

Or<\/p>\n\n\n\n

Access the Ebola Viral\u00a0Infections Pipeline Insights report here: Healthcare Market Research Reports<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

Get informed about the Current Drugs in Pipeline with DelveInsight \u201c’Ebola Viral Infections–Pipeline Insights, 2014\u2032, Report About Virus Ebola virus disease (formerly known as Ebola haemorrhagic fever) is a severe, often fatal illness, with a case fatality rate of up to 90%. Ebola first appeared in 1976 in 2 simultaneous outbreaks, in Nzara, Sudan, and in […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":3,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[101,147,193,194,204,220,221,223,224,225,244,472,488,520,559,560,586,595,597,607,611],"industry":[17225],"therapeutic_areas":[17231],"class_list":["post-70","post","type-post","status-publish","format-standard","hentry","category-articles","tag-avi-7537","tag-cases-and-death","tag-current-treatment","tag-currently-given-non-licensed-drug","tag-delveinsight","tag-ebola","tag-ebola-approved-drugs","tag-ebola-pipeline","tag-ebola-virus-infection","tag-ebolavirus","tag-fast-track-drugs","tag-phase-i","tag-plants","tag-risk","tag-tekmira","tag-tekmira-pharmaceuticals-corporation","tag-u-s-food-and-drug-administration","tag-usfda","tag-vaccine-and-treatment","tag-west-africa","tag-zmapp","industry-pharmaceutical","therapeutic_areas-infectious-diseases"],"acf":[],"yoast_head":"\nEbola Virus Presnet Drugs and Pipeline therapies | DelveInsight<\/title>\n<meta name=\"description\" content=\"Ebola virus disease (formerly known as Ebola haemorrhagic fever) is a severe, often fatal illness, with a case fatality rate of up to 90%.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/ebola-virus-drugs-approved-or-still-in-pipeline-whats-the-mystery\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ebola Virus Presnet Drugs and Pipeline therapies | DelveInsight\" \/>\n<meta property=\"og:description\" content=\"Ebola virus disease (formerly known as Ebola haemorrhagic fever) is a severe, often fatal illness, with a case fatality rate of up to 90%.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/ebola-virus-drugs-approved-or-still-in-pipeline-whats-the-mystery\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-08-20T13:17:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-02-06T10:07:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2021\/08\/Total-Cases-West-Africa-Ebola-Virus.png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ebola Virus Presnet Drugs and Pipeline therapies | DelveInsight","description":"Ebola virus disease (formerly known as Ebola haemorrhagic fever) is a severe, often fatal illness, with a case fatality rate of up to 90%.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/ebola-virus-drugs-approved-or-still-in-pipeline-whats-the-mystery","og_locale":"en_US","og_type":"article","og_title":"Ebola Virus Presnet Drugs and Pipeline therapies | DelveInsight","og_description":"Ebola virus disease (formerly known as Ebola haemorrhagic fever) is a severe, often fatal illness, with a case fatality rate of up to 90%.","og_url":"https:\/\/www.delveinsight.com\/blog\/ebola-virus-drugs-approved-or-still-in-pipeline-whats-the-mystery","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2014-08-20T13:17:06+00:00","article_modified_time":"2023-02-06T10:07:54+00:00","og_image":[{"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2021\/08\/Total-Cases-West-Africa-Ebola-Virus.png","type":"","width":"","height":""}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/ebola-virus-drugs-approved-or-still-in-pipeline-whats-the-mystery","url":"https:\/\/www.delveinsight.com\/blog\/ebola-virus-drugs-approved-or-still-in-pipeline-whats-the-mystery","name":"Ebola Virus Presnet Drugs and Pipeline therapies | DelveInsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/ebola-virus-drugs-approved-or-still-in-pipeline-whats-the-mystery#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/ebola-virus-drugs-approved-or-still-in-pipeline-whats-the-mystery#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2021\/08\/Total-Cases-West-Africa-Ebola-Virus.png","datePublished":"2014-08-20T13:17:06+00:00","dateModified":"2023-02-06T10:07:54+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Ebola virus disease (formerly known as Ebola haemorrhagic fever) is a severe, often fatal illness, with a case fatality rate of up to 90%.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/ebola-virus-drugs-approved-or-still-in-pipeline-whats-the-mystery"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/ebola-virus-drugs-approved-or-still-in-pipeline-whats-the-mystery#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/08\/23121732\/Total-Cases-West-Africa-Ebola-Virus.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/08\/23121732\/Total-Cases-West-Africa-Ebola-Virus.png","width":400,"height":174},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">AVI-7537<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Cases and Death<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Current Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Currently Given Non-Licensed Drug<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Ebola<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Ebola Approved Drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">ebola pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Ebola Virus Infection<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Ebolavirus<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Fast Track Drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Phase I<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">plants<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">RISK<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Tekmira<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Tekmira Pharmaceuticals Corporation.<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">U.S. Food and Drug Administration<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">USFDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Vaccine and treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">West Africa<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">ZMapp<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AVI-7537<\/span>","<span class=\"advgb-post-tax-term\">Cases and Death<\/span>","<span class=\"advgb-post-tax-term\">Current Treatment<\/span>","<span class=\"advgb-post-tax-term\">Currently Given Non-Licensed Drug<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Ebola<\/span>","<span class=\"advgb-post-tax-term\">Ebola Approved Drugs<\/span>","<span class=\"advgb-post-tax-term\">ebola pipeline<\/span>","<span class=\"advgb-post-tax-term\">Ebola Virus Infection<\/span>","<span class=\"advgb-post-tax-term\">Ebolavirus<\/span>","<span class=\"advgb-post-tax-term\">Fast Track Drugs<\/span>","<span class=\"advgb-post-tax-term\">Phase I<\/span>","<span class=\"advgb-post-tax-term\">plants<\/span>","<span class=\"advgb-post-tax-term\">RISK<\/span>","<span class=\"advgb-post-tax-term\">Tekmira<\/span>","<span class=\"advgb-post-tax-term\">Tekmira Pharmaceuticals Corporation.<\/span>","<span class=\"advgb-post-tax-term\">U.S. Food and Drug Administration<\/span>","<span class=\"advgb-post-tax-term\">USFDA<\/span>","<span class=\"advgb-post-tax-term\">Vaccine and treatment<\/span>","<span class=\"advgb-post-tax-term\">West Africa<\/span>","<span class=\"advgb-post-tax-term\">ZMapp<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 12 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Aug 20, 2014","modified":"Updated on Feb 6, 2023"},"absolute_dates_time":{"created":"Posted on Aug 20, 2014 1:17 pm","modified":"Updated on Feb 6, 2023 3:37 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/70","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=70"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/70\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=70"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=70"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=70"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=70"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=70"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}